The (often referred to simply as the IFM-05 study) focused on using lenalidomide as a maintenance treatment.
One critical finding was an increased risk of developing a second primary malignancy (SPM) while on long-term lenalidomide maintenance. Patient Considerations IFM_05-May 2022
The study demonstrated a clear overall survival benefit for patients receiving maintenance therapy compared to a placebo. The (often referred to simply as the IFM-05
To determine if continuous low-dose chemotherapy after a transplant could improve overall survival and keep the disease controlled for longer periods. IFM_05-May 2022